ema prac naion semaglutide june 2025 Is Linked to NAION? A Case Report on a Rare Ocular Complication FDA Sends Warning Letter to
Description
When administered, the peptide preferentially accumulates in adipose tissue, where it interacts with beta-3 adrenergic receptors on fat cell membranes and initiates metabolic signaling cascades
J., Whitledge, J
Watch the video and let us know what you think
Hanmi Pharmaceutical has started dosing patients in a Korean phase 3 trial of efpeglenatide for type 2 diabetes, adding a second late-stage path for the GLP-1 drug after filing it as an obesity treatment
